Aetna to end payment for a drug in colonoscopies

Aetna is the latest insurer to clamp down on the use of a powerful anesthetic during an increasingly common form of colon cancer screening. The company will send a letter to doctors, saying that it plans to classify the drug as "medically unnecessary" for most such procedures. As of April 1, Aetna plans to stop paying for its use in those cases. The change by Aetna comes on the heels of similar moves last year by WellPoint and six months ago by Humana. Other insurers say they have no plans to follow their lead, including UnitedHealthcare.